Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease

Journal of Chemical Neuroanatomy

Volumn 42, Issue 2, 2011, Pages 111-117

  Counts, Scott E ^a   Che, Shaoli ^b,c   Ginsberg, Stephen D ^b,c,d   Mufson, Elliott J ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Cholinergic basal forebrain; Gender; Microarray; Mild cognitive impairment; Nerve growth factor

Indexed keywords

AMPA RECEPTOR; GLUTAMATE RECEPTOR; MESSENGER RNA; NEUROTROPHIN; PROTEIN P75; PROTEIN TYROSINE KINASE A; RNA;

AGED; ALZHEIMER DISEASE; ARTICLE; BASAL AMYGDALA; CELL DEATH; CHOLINERGIC NERVE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BASAL NUCLEUS OF MEYNERT; CELL DEATH; CHOLINERGIC NEURONS; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; HUMANS; MALE; NERVE GROWTH FACTOR; RECEPTOR, NERVE GROWTH FACTOR; RECEPTOR, TRKA; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RISK FACTORS; SEX CHARACTERISTICS; SEX DISTRIBUTION;

EID: 80052097387     PISSN: 08910618     EISSN: 18736300     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2011.02.004     Document Type: Article

References (61)

1. Aarsland D., Larsen J.P., Reinvang I., Aasland A.M. Effects of cholinergic blockade on language in healthy young women. Implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain 1994, 117(Pt 6):1377-1384.
2. Alvarez-de-la-Rosa M., Silva I., Nilsen J., Perez M.M., Garcia-Segura L.M., Avila J., Naftolin F. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer's disease. Ann. N. Y. Acad. Sci. 2005, 1052:210-224.
3. Ancelin M.L., Artero S., Portet F., Dupuy A.M., Touchon J., Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal Cohort Study. BMJ 2006, 332:455-459.
4. Andersen K., Launer L.J., Dewey M.E., Letenneur L., Ott A., Copeland J.R., Dartigues J.F., Kragh-Sorensen P., Baldereschi M., Brayne C., Lobo A., Martinez-Lage J.M., Stijnen T., Hofman A. Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. EURODEM Incidence Research Group. Neurology 1999, 53:1992-1997.
5. Baxter M.G., Chiba A.A. Cognitive functions of the basal forebrain. Curr. Opin. Neurobiol. 1999, 9:178-183.
6. Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Beckett L.A., Aggarwal N.T., Barnes L.L., Fox J.H., Bach J. Natural history of mild cognitive impairment in older persons. Neurology 2002, 59:198-205.
7. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. Annu. Rev. Neurosci. 1995, 18:223-253.
8. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
9. Buckwalter J.G., Rizzo A.A., McCleary R., Shankle R., Dick M., Henderson V.W. Gender comparisons of cognitive performances among vascular dementia. Alzheimer disease, and older adults without dementia. Arch. Neurol. 1996, 53:436-439.
10. Carnes K.M., Fuller T.A., Price J.L. Sources of presumptive glutamatergic/aspartatergic afferents to the magnocellular basal forebrain in the rat. J. Comp. Neurol. 1990, 302:824-852.
11. Che S., Ginsberg S.D. Amplification of RNA transcripts using terminal continuation. Lab. Invest. 2004, 84:131-137.
12. Counts S.E., He B., Che S., Ginsberg S.D., Mufson E.J. Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease. J. Alzheimers Dis. 2009, 18:885-896.
13. Counts S.E., He B., Che S., Ikonomovic M.D., DeKosky S.T., Ginsberg S.D., Mufson E.J. Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch. Neurol. 2007, 64:1771-1776.
14. Counts S.E., Mufson E.J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J. Neuropathol. Exp. Neurol. 2005, 64:263-272.
15. Dominguez R., Jalali C., de Lacalle S. Morphological effects of estrogen on cholinergic neurons in vitro involves activation of extracellular signal-regulated kinases. J. Neurosci. 2004, 24:982-990.
16. Gibbs R.B. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Exp. Neurol. 1998, 151:289-302.
17. Gibbs R.B., Burke A.M., Johnson D.A. Estrogen replacement attenuates effects of scopolamine and lorazepam on memory acquisition and retention. Horm. Behav. 1998, 34:112-125.
18. Ginsberg S.D. RNA amplification strategies for small sample populations. Methods 2005, 37:229-237.
19. Ginsberg S.D., Alldred M.J., Counts S.E., Cataldo A.M., Neve R.L., Jiang Y., Wuu J., Chao M.V., Mufson E.J., Nixon R.A., Che S. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer's disease progression. Biol. Psychiatry 2010, 68:885-893.
20. Ginsberg S.D., Che S., Wuu J., Counts S.E., Mufson E.J. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J. Neurochem. 2006, 97:475-487.
21. Ginsberg S.D., Portera-Cailliau C., Martin L.J. Fimbria-fornix transection and excitotoxicity produce similar neurodegeneration in the septum. Neuroscience 1999, 88:1059-1071.
22. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
23. Henderson V.W., Buckwalter J.G. Cognitive deficits of men and women with Alzheimer's disease. Neurology 1994, 44:90-96.
24. Houeland G., Romani A., Marchetti C., Amato G., Capsoni S., Cattaneo A., Marie H. Transgenic mice with chronic NGF deprivation and Alzheimer's disease-like pathology display hippocampal region-specific impairments in short- and long-term plasticities. J. Neurosci. 2010, 30:13089-13094.
25. Hyman B.T., Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56:1095-1097.
26. Jorm A.F., Korten A.E., Henderson A.S. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr. Scand. 1987, 76:465-479.
27. Kaplan D.R., Miller F.D. Signal transduction by the neurotrophin receptors. Curr. Opin. Cell Biol. 1997, 9:213-221.
28. Kaplan D.R., Stephens R.M. Neurotrophin signal transduction by the trk receptor. J. Neurobiol. 1994, 25:1404-1417.
29. Klesse L.J., Parada L.F. Trks: signal transduction and intracellular pathways. Microsc. Res. Technol. 1999, 45:210-216.
30. Lad S.P., Neet K.E., Mufson E.J. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr. Drug Target CNS Neurol. Disord. 2003, 2:315-334.
31. Launer L.J., Andersen K., Dewey M.E., Letenneur L., Ott A., Amaducci L.A., Brayne C., Copeland J.R., Dartigues J.F., Kragh-Sorensen P., Lobo A., Martinez-Lage J.M., Stijnen T., Hofman A. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and work groups. European studies of dementia. Neurology 1999, 52:78-84.
32. Lechevallier-Michel N., Molimard M., Dartigues J.F., Fabrigoule C., Fourrier-Reglat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the Paquid study. Br. J. Clin. Pharmacol. 2005, 59:143-151.
33. Liu S., Lau L., Wei J., Zhu D., Zou S., Sun H.S., Fu Y., Liu F., Lu Y. Expression of Ca(2+)-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. Neuron 2004, 43:43-55.
34. Lourenssen S., Roder J.C., Blennerhassett M.G. Absence of the GluR2 receptor sensitizes mouse sympathetic neurons to nerve growth factor deprivation. Neurosci. Lett. 2000, 281:25-28.
35. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984, 34:939-944.
36. McMillan P.J., Singer C.A., Dorsa D.M. The effects of ovariectomy and estrogen replacement on trka and choline acetyltransferase mRNA expression in the basal forebrain of the adult female Sprague-Dawley rat. J. Neurosci. 1996, 16:1860-1865.
37. Michel P.P., Agid Y. Death of septal cholinergic neurons produced by chronic exposure to glutamate is prevented by the noncompetitive NMDA receptor/channel antagonist, MK-801: role of nerve growth factor and nitric oxide. J. Neurosci. Res. 1995, 40:764-775.
38. Miller F.D., Hicks S.P., D'Amato C.J., Landis J.R. A descriptive study of neuritic plaques and neurofibrillary tangles in an autopsy population. Am. J. Epidemiol. 1984, 120:331-341.
39. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
40. Mufson E.J., Bothwell M., Hersh L.B., Kordower J.H. Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: colocalization with cholinergic neurons. J. Comp. Neurol. 1989, 285:196-217.
41. Mufson E.J., Chen E.Y., Cochran E.J., Beckett L.A., Bennett D.A., Kordower J.H. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp. Neurol. 1999, 158:469-490.
42. Mufson E.J., Counts S.E., Fahnestock M., Ginsberg S.D. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr. Alzheimer Res. 2007, 4:340-350.
43. Mufson E.J., Counts S.E., Ginsberg S.D. Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochem. Res. 2002, 27:1035-1048.
44. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J. Chem. Neuroanat. 2003, 26:233-242.
45. Ott A., Breteler M.M., van Harskamp F., Stijnen T., Hofman A. Incidence and risk of dementia. The Rotterdam Study. Am. J. Epidemiol. 1998, 147:574-580.
46. Ott B.R. Cognition and behavior in patients with Alzheimer's disease. J. Gend. Specif. Med. 1999, 2:63-69.
47. Parks R.W., Becker R.E., Rippey R.F., Gilbert D.G., Matthews J.R., Kabatay E., Young C.S., Vohs C., Danz V., Keim P., Collins G.T., Zigler S.S., Urycki P.G. Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study. Neuropsychol. Rev. 1996, 6:61-79.
48. Peng S., Wuu J., Mufson E.J., Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer's disease. J. Neuropathol. Exp. Neurol. 2004, 63:641-649.
49. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256:183-194.
50. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 2001, 58:1985-1992.
51. Reiner A., Yekutieli D., Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003, 19:368-375.
52. Salehi A., Gonzalez Martinez V., Swaab D.F. A sex difference and no effect of apoe type on the amount of cytoskeletal alterations in the nucleus basalis of Meynert in Alzheimer's disease. Neurobiol. Aging 1998, 19:505-510.
53. Sandberg G., Stewart W., Smialek J., Troncoso J.C. The prevalence of the neuropathological lesions of Alzheimer's disease is independent of race and gender. Neurobiol. Aging 2001, 22:169-175.
54. Sobreviela T., Clary D.O., Reichardt L.F., Brandabur M.M., Kordower J.H., Mufson E.J. Trka-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J. Comp. Neurol. 1994, 350:587-611.
55. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 2001, 24:1217-1281.
56. Tanaka Y., Miyazaki M., Albert M.L. Effects of increased cholinergic activity on naming in aphasia. Lancet 1997, 350:116-117.
57. Toran-Allerand C.D., Singh M., Setalo G. Novel mechanisms of estrogen action in the brain: new players in an old story. Front. Neuroendocrinol. 1999, 20:97-121.
58. Tuszynski M.H., Thal L., Pay M., Salmon D.P.U.H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., Tong G., Potkin S.G., Fallon J., Hansen L., Mufson E.J., Kordower J.H., Gall C., Conner J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11:551-555.
59. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10:122-126.
60. Wimo, A., Jonsson, L., Gustavsson, A., McDaid, D., Ersek, K., Georges, J., Gulacsi, L., Karpati, K., Kenigsberg, P., Valtonen, H. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode Project. Int. J. Geriatr. Psychiatry, e-published in 2010.
61. Zaborszky L., Gaykema R.P., Swanson D.J., Cullinan W.E. Cortical input to the basal forebrain. Neuroscience 1997, 79:1051-1078.